- A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction.
A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction.
Journal of addictive diseases (2013-03-14)
Anne M Neumann, Richard D Blondell, Urmo Jaanimägi, Amanda K Giambrone, Gregory G Homish, Jacqueline R Lozano, Urszula Kowalik, Mohammadreza Azadfard
PMID23480249
RÉSUMÉ
Patients with opioid addiction who receive prescription opioids for treatment of nonmalignant chronic pain present a therapeutic challenge. Fifty-four participants with chronic pain and opioid addiction were randomized to receive methadone or buprenorphine/naloxone. At the 6-month follow-up examination, 26 (48.1%) participants who remained in the study noted a 12.75% reduction in pain (P = 0.043), and no participants in the methadone group compared to 5 in the buprenorphine group reported illicit opioid use (P = 0.039). Other differences between the two conditions were not found. Long-term, low-dose methadone or buprenorphine/naloxone treatment produced analgesia in participants with chronic pain and opioid addiction.
MATÉRIAUX
Numéro du produit
Marque
Description du produit
Le tarif et la disponibilité ne sont pas disponibles actuellement.
Supelco
Naloxone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Le tarif et la disponibilité ne sont pas disponibles actuellement.